OncoMatch/Clinical Trials/NCT06249321
mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
Is NCT06249321 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies mFOLFIRINOX plus IMRT for pancreatic cancer.
Treatment: mFOLFIRINOX plus IMRT — The purpose of this study is to evaluate the efficacy of mFOLFIRINOX plus radiotherapy to Patients with CA19-9-normal Advanced Pancreatic Cancer refractory to chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Pancreatic Cancer
Biomarker criteria
Required: FUT3 CA19-9 ≤ 37 U/mL (≤ 37 U/mL)
Baseline serum CA19-9 ≤ 37 U/mL
Required: CEACAM5 CEA ≤ 5.2 ng/mL (≤ 5.2 ng/mL)
CEA≤ 5.2 ng/mL
Required: MUC16 CA125 ≤ 35 U/mL (≤ 35 U/mL)
CA125 ≤ 35 U/mL
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: chemotherapy
Patients who are refractory to at least one line of chemotherapy
Cannot have received: radiotherapy
who have not received radiotherapy
Lab requirements
Kidney function
Renal insufficiency or dialysis [excluded]
Adequate organ performance based on laboratory blood tests. Renal insufficiency or dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify